Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 11/20 | 0.45 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56783 | 1.00 | CA1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL56671 | 1.00 | CA1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL3685399 | 0.86 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23925023 | 0.86 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL14496991 | 0.86 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1352540 | 0.85 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL31255051 | 0.85 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1692753 | 0.85 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL22362992 | 0.85 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL30365028 | 0.85 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340554-A1 | 5-Amino-1H-Pyrrolo[3,2-b]Pyridine-2-Carboxamide Derivatives as MTA-Cooperative Inhibitors of PRMT5 | BEONE MEDICINES I GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| CN-115279767-B | Tetracyclic compounds as inhibitors of hepatitis b surface antigen | 正大天晴药业集团股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-113166143-B | N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions and methods | 舒万诺知识产权公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3887369-B1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-110831942-B | Fused indazolopyridinone compounds as antiviral agents | 诺华股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115279767-A | Tetracyclic compounds as inhibitors of hepatitis B surface antigen | 正大天晴药业集团股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-110831942-A | Fused indazolopyridinone compounds as antiviral agents | 诺华股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| EP-3162438-A1 | POLYMER SUPPORTED VICINAL DIAMINES AND THEIR USE AS CATALYST IN THE HAJOS-PARRISH-ENDER-SAUSER-WIECHERT AND ROBINSON ANNULATION REACTIONS | Fundació Institut Català d'Investigació Química (ES) | 2017-05-03 | — | — | EP | disclosed |
| WO-2008070358-A2 | N-CYCLOPROPYL-HYDROXYPROLINE-BASED TRIPEPTIDIC HEPATITIS C SERINE PROTEASE INHIBITORS CONTAINING AN ISOINDOLE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE OR PYRROLOPYRAZINE HETEROCYCLE IN THE SIDE CHAIN | PHENOMIX CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340554-A1 | 5-Amino-1H-Pyrrolo[3,2-b]Pyridine-2-Carboxamide Derivatives as MTA-Cooperative Inhibitors of PRMT5 | PRMT5, PRMT1, PRMT3 | CA1 4280/4885CA2 3582/4885CA7 4475/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | CA1 548/4885CA2 597/4885CA7 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.